Encorafenib | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Encorafenib
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

Encorafenib

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

10 API Suppliers, 3 USDMF, 1 EU WC, 4 NDC API, 6 Listed Suppliers, $ API Reference Price

10 API Suppliers
3 USDMF
1 EU WC
4 NDC API
6 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

79 Drugs in Development

79 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

12 FDF Dossiers, 2 FDA Orange Book, 3 Europe, 1 Canada, 6 Australia

12 FDF Dossiers
2 FDA Orange Book
3 Europe
1 Canada
6 Australia

DIGITAL CONTENT

55 News #PharmaBuzz

55 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 3 Regulatory FDF Prices, 9 Annual Reports

1 US Medicaid Prescriptions
3 Regulatory FDF Prices
9 Annual Reports

MARKET PLACE

2 APIs, 3 FDF Dossiers

2 APIs
3 FDF Dossiers

PATENTS & EXCLUSIVITIES

41 US Patents, 8 US Exclusivities, 5 Health Canada Patents

41 US Patents
8 US Exclusivities
5 Health Canada Patents

$ API Ref.Price (USD/KG) : 22,998 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

5 All

01 5Pfizer Canada ULC

filter Patent Reset all filters

5 All

01 12731146

02 12771775

03 12856406

04 12879548

05 12907704

filter Product Reset all filters

5 All

01 5ENCORAFENIB

filter Dosage Reset all filters

5 All

01 5CAPSULE

filter Exp Date Reset all filters

5 All

01 12029-07-23

02 12030-08-27

03 12032-11-21

04 12033-08-05

05 12034-03-19

Product Main Page

01

Pfizer Canada ULC

Encorafenib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-07-23

Date Granted : 2016-05-03

Encorafenib

Brand Name : BRAFTOVI

Patent Number : 2731146

Filing Date : 2009-07-23

Strength per Unit : 75 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2029-07-23

Date Granted : 2016-05-03

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Pfizer Canada ULC

Encorafenib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-08-27

Date Granted : 2015-01-20

Encorafenib

Brand Name : BRAFTOVI

Patent Number : 2771775

Filing Date : 2010-08-27

Strength per Unit : 75 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2030-08-27

Date Granted : 2015-01-20

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Pfizer Canada ULC

Encorafenib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-11-21

Date Granted : 2020-06-23

Encorafenib

Brand Name : BRAFTOVI

Patent Number : 2856406

Filing Date : 2012-11-21

Strength per Unit : 75 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-11-21

Date Granted : 2020-06-23

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Pfizer Canada ULC

Encorafenib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2033-08-05

Date Granted : 2020-07-21

Encorafenib

Brand Name : BRAFTOVI

Patent Number : 2879548

Filing Date : 2013-08-05

Strength per Unit : 75 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2033-08-05

Date Granted : 2020-07-21

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Pfizer Canada ULC

Encorafenib

CPHI Shenzhen

Not Confirmed

Pfizer Canada ULC

Country

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2034-03-19

Date Granted : 2023-01-10

Encorafenib

Brand Name : BRAFTOVI

Patent Number : 2907704

Filing Date : 2014-03-19

Strength per Unit : 75 mg

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2034-03-19

Date Granted : 2023-01-10

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!